Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bicycle Therapeutics (BCYC) EBIT (2018 - 2025)

Bicycle Therapeutics' EBIT history spans 8 years, with the latest figure at $167.7 million for Q4 2025.

  • For Q4 2025, EBIT rose 347.78% year-over-year to $167.7 million; the TTM value through Dec 2025 reached -$54.7 million, up 73.94%, while the annual FY2025 figure was -$54.7 million, 73.94% up from the prior year.
  • EBIT reached $167.7 million in Q4 2025 per BCYC's latest filing, up from -$65.6 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $167.7 million in Q4 2025 to a low of -$86.6 million in Q2 2025.
  • Average EBIT over 5 years is -$31.8 million, with a median of -$37.0 million recorded in 2022.
  • The largest YoY upside for EBIT was 347.78% in 2025 against a maximum downside of 121.35% in 2025.
  • A 5-year view of EBIT shows it stood at -$18.0 million in 2021, then crashed by 78.71% to -$32.2 million in 2022, then crashed by 68.37% to -$54.2 million in 2023, then fell by 24.76% to -$67.7 million in 2024, then soared by 347.78% to $167.7 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's EBIT are $167.7 million (Q4 2025), -$65.6 million (Q3 2025), and -$86.6 million (Q2 2025).